PET/CT with 68Ga-FAPI and 18F-FDG in the Detection of Distant Metastases of Gastric Cancer
https://doi.org/10.37174/2587-7593-2026-9-1-16-23
Abstract
Purpose: To determine the diagnostic effectiveness of PET/CT with 68Ga-FAPI in the detection and staging of metastases in patients with gastric cancer. Material and methods: The study included 57 patients with histologically confirmed gastric cancer. All patients underwent PET/CT with 68Ga-FAPI and PET/CT with 18F-FDG. The diagnostic accuracy of the methods was compared based on sensitivity and specificity parameters in detecting distant metastatic lesions. Data assessment was conducted based on histologically verified disease and clinical follow-up data. Results: 57 patients underwent both 68Ga-FAPI PET/CT and 18F-FDG PET/CT. In 5 patients (8.7 %), the treatment plan was changed from radical to palliative based on the 68Ga-FAPI PET/CT results. 68Ga-FAPI PET/CT detected distant metastases in 29 patients (50.8 %), while with 18F-FDG, distant metastases were detected in 18 patients (31.5 %). The sensitivity of 68Ga-FAPI PET/CT in detecting distant metastases was 100 %, with a specificity of 85.7 %, whereas for 18F-FDG, these values were 62 % and 90 %, respectively. Conclusion: PET/CT with 68Ga-FAPI is a more effective diagnostic method for detecting distant metastases of gastric cancer than PET/ CT with 18F-FDG. The obtained results indicate the need to use PET/CT with 68Ga-FAPI in clinical practice for more accurate diagnosis and treatment strategy selection in gastric cancer.
About the Authors
E. V. Belkin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared.
P. E. Tulin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared.
A. M. Badeyan
Radioisotope Production Centre
Armenia
Competing Interests:
Armenia
38/7, Alabyana str., Yerevan
Competing Interests:
Not declared.
O. B. Abu‑Khaidar
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared.
V. V. Solomyanyy
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared.
A. V. Filimonov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Competing Interests:
Not declared.
References
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLO BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229-63. https://doi.org/10.3322/caac.21834.
2. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153(2):420-9. https://doi.org/10.1053/j.gastro.2017.04.022.
3. Kim H, Hwang Y, Sung H, et al. Effectiveness of gastric cancer screen ing on gastric cancer incidence and mortality in a community-based prospective cohort. Cancer Res Treat. 2018;50(2):582-89. https://doi.org/10.4143/crt.2017.048.
4. Hamashima C, Ogoshi K, Okamoto M, et al. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One 2013;8(11):e79088. https://doi.org/10.1371/journal.pone.0079088.
5. Jun JK, Choi KS, Lee H-Y, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology 2017;152(6):1319-28.e7. https://doi.org/10.1053/j.gastro.2017.01.029.
6. Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut 2020;69(5):823-9. https://doi.org/10.1136/gutjnl-2019-320234.
7. Besova NS, Bolotina LV, Gamayunov SV, et al. Gastric Cancer. Practical Guidelines RUSSCO, Part 1.1. Malignant Tumours 2024;14(3s2):241– 262 (In Russ.). https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-13.
8. Clinical Guidelines. Gastric Cancer. Clinical Guidelines of the Association of Oncologists of Russia and the Russian Society of Clinical Oncology. 2020. AOR (Internet). https://oncology-association.ru.
9. Muto M, Saito S, Muto M, et al. Effect of adding X-ray examination to endoscopy in the assessment of the invasion depth of early gastric cancer. Nihon Shokakibyo Gakkai Zasshi 2019;116(6):506-14. https://doi.org/10.11405/nisshoshi.116.506.
10. Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):19-33. https://doi.org/10.1093/annonc/mdy502.
11. Seo N, Lim JS, Cho A Radiologic Diagnosis (CT, MRI, & PET-CT). In: Noh, S, Hyung, W. (eds). Surgery for Gastric Cancer. Berlin: Springer. 2019: 67-86. https://doi.org/10.1007/978-3-662-45583-8_4.
12. Wang Y, Liu W, Yu Y, et al. CT radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer. Eur Radiol. 2020;30(2):976-86. https://doi.org/10.1007/s00330-019-06398-z.
13. National Comprehensive Cancer Network, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guide-lines®): Gastric. Cancer. Version 5.2024. www.nccn.org.
14. Rays AB, Fedyanin MYu, Popov DV, et al. Prognostic and predictive factors in patients with metastatic gastric cancer treated with immune checkpoint inhibitors. Surgery and Oncology. 2024;14(4):73 85. (In Russ.). https://doi.org/10.17650/2949-5857-2024-14-4-73-85
15. Emma G, Hylke B, Richard van Hillegersberg, et al. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multi center Prospective Dutch Cohort Study (PLASTIC). JAMA Surg. 2021 Oct 27;156(12):e215340. https://doi.org/10.1001/jamasurg.2021.5340.
16. Kobayashi S, Ogura M, Suzawa N, et al. 18F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis. BMC Med Imaging. 2016;16(1):58. https://doi.org/10.1186/s12880-016-0161-9.
17. Yin C, Gao B, Yang J, et al. Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer. Med Sci Monit Basic Res 2020;26:e920778. https://doi.org/10.12659/MSMBR.920778.
18. Hamson E J, Keane F M, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5-6):454-63. https://doi.org/10.1002/prca.201300095.
19. Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, et al. FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric and Cholangiocarcinoma: Systematic Review and Head-to-Head Compari sons of Diagnostic Performances. Diagnostics (Basel). 2022;12(8):1958. https://doi.org/10.3390/diagnostics12081958.
20. Qin C, Shao F, Gai Y, et al. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022;63(1):81-8. https://doi.org/10.2967/jnumed.120.258467.
21. Ruan D, Zhao L, Cai J, et al. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. Theranostics. 2023;13(13):4694-710. https://doi.org/10.7150/thno.88335.
22. Belkin EV, Tulin PE, Abu-Khaydar OB, et al. PET/CT with 68Ga FAPI and 18F-FDG in the Detection of Metastases in Regional Lymph Nodes in Gastric Cancer. Journal of oncology: diagnostic radiology and radiotherapy. 2025;8(1):29-35. (In Russ.) https://doi.org/10.37174/2587-7593-2025-8-1-29-35.
23.
Review
For citations:
Belkin E.V., Tulin P.E., Badeyan A.M., Abu‑Khaidar O.B., Solomyanyy V.V., Filimonov A.V. PET/CT with 68Ga-FAPI and 18F-FDG in the Detection of Distant Metastases of Gastric Cancer. Journal of oncology: diagnostic radiology and radiotherapy. 2026;9(1):16-23. (In Russ.) https://doi.org/10.37174/2587-7593-2026-9-1-16-23
Views:
226
JATS XML
Email this article 